The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
FDA agrees to a rolling review towards the BLA for remestemcel-l in the treatment of aGvHD
The FDA has agreed to a rolling review towards the first component of a rolling submission for a Biologics License Application (BLA) for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (aGVHD).
The application enables individual components of the review to be submitted and evaluated on an ongoing basis rather than waiting for all sections to be completed. This approach will provide an opportunity for open-ended communication, and allow ample time for any matters raised by the FDA to be adequately addressed. Under this designation, a priority review can be requested; following the completion of the BLA.
Trial information
The Phase III trial of 55 children (six months - 17 years) with aGVHD - 89% of that had Grade C/D disease - treatment with remestemcel-L resulted in a six-month survival of 69%.
The trial showed an Overall Response (OR) at day 28, which occurred in 69% of patients, predicted the highest survival at Day 100 and Day 180, which was 85% and 79%, respectively. The phase III trial met its primary endpoint of increased Day 28 OR compared with a protocol-defined historical control rate of 45% ( P = 0.0003). This data was found to be consistent with previous results where remestemcel-L was used as salvage therapy after failure of steroids and other agents.
References